Titus Wealth Management Sells 1,535 Shares of Pfizer Inc. (NYSE:PFE)

Titus Wealth Management lessened its stake in Pfizer Inc. (NYSE:PFE) by 7.8% during the second quarter, Holdings Channel reports. The firm owned 18,162 shares of the biopharmaceutical company’s stock after selling 1,535 shares during the period. Pfizer makes up approximately 0.8% of Titus Wealth Management’s portfolio, making the stock its 28th largest position. Titus Wealth Management’s holdings in Pfizer were worth $787,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of PFE. Evolution Wealth Advisors LLC bought a new stake in Pfizer during the second quarter worth $34,000. IMA Wealth Inc. lifted its holdings in Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 477 shares during the period. Winch Advisory Services LLC lifted its holdings in Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 336 shares during the period. Financial Gravity Wealth Inc. lifted its holdings in Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 257 shares during the period. Finally, Karp Capital Management Corp bought a new stake in Pfizer during the fourth quarter worth $53,000. Institutional investors own 71.68% of the company’s stock.

PFE has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target on the stock in a report on Wednesday, August 28th. UBS Group reiterated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $45.88.



In related news, Director Scott Gottlieb purchased 3,000 shares of Pfizer stock in a transaction dated Friday, August 23rd. The stock was bought at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $104,160. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction dated Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

NYSE:PFE traded down $0.11 during trading hours on Wednesday, reaching $35.90. The stock had a trading volume of 19,254,813 shares, compared to its average volume of 20,765,358. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The stock has a 50 day simple moving average of $35.87 and a 200 day simple moving average of $40.43. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The stock has a market cap of $202.93 billion, a P/E ratio of 11.97, a price-to-earnings-growth ratio of 2.92 and a beta of 0.66.

Pfizer (NYSE:PFE) last released its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business posted $0.77 earnings per share. The business’s revenue for the quarter was down 1.5% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 4.01%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.